aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results

by · The Cerbat Gem

aTyr Pharma (NASDAQ:ATYR – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($7.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43), FiscalAI reports.

aTyr Pharma Trading Down 2.4%

ATYR stock traded down $0.15 during mid-day trading on Thursday, hitting $6.03. 58,833 shares of the company were exchanged, compared to its average volume of 100,043. The business has a 50 day simple moving average of $11.99 and a 200-day simple moving average of $23.70. The stock has a market capitalization of $14.77 million, a PE ratio of -0.24 and a beta of 1.04. aTyr Pharma has a 1-year low of $4.07 and a 1-year high of $44.40.

Analyst Ratings Changes

A number of analysts have recently issued reports on ATYR shares. Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Wall Street Zen raised aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Get Our Latest Analysis on aTyr Pharma

About aTyr Pharma

(Get Free Report)

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.

Read More